期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿立哌唑的波谱特征与结构确证 被引量：5

暂未订购
导出
摘要 目的通过分析仪器测定的数据,确定阿立哌唑的结构。方法对阿立哌唑的红外、紫外、质谱、氢-氢相关谱、碳谱、碳-氢相关谱、碳-氢远程相关谱予以解析,对所有的磁共振的碳、氢谱信号进行归属;通过红外特征吸收峰所对应的官能团的振动形式,对样品进行差热和热重分析。结果精制品和对照品的熔点基本一致。结论根据谱学特征确证了阿立哌唑的结构,该方法为此类化合物的结构解析提供了客观的科学数据和理论分析依据。
作者 卜跃华 洪博 蔡心怡 赵春杰
机构地区 中国医科大学高等职业技术学院 沈阳药科大学药学院
出处 《医药导报》 CAS 2009年第12期1546-1548,共3页 Herald of Medicine
关键词 阿立哌唑 药物化学 结构确证 波谱特征
分类号 R971.41 [医药卫生—药品]
  • 相关文献

参考文献5

二级参考文献15

  • 1Butini S, Campiani G, Angelis MD, et al. Novel antipsychotic agents:recent advances in the drug treatment of schizophrenia [J].Expert Opinion on Therapeutic Patents, 2003, 13(4): 425.
  • 2Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials [J]. Schizophr Res, 2003, 61 (2～3):123.
  • 3Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug[J]. Ann Pharmacother, 2003, 37(5): 687.
  • 4Bristol-Myers Squibb Company. ABILIFY (aripiprazole) Tablets[EB/OL]. http://www.bms.com/cgi-bin/anybin.pl? sql = select％20PPI％ 20from％ 20TB_PRODUCT_PPI％ 20where％ 20PPI_SEQ =101&key = PPI, 2002-11-15/2003-07-17.
  • 5Keck Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic[J]. Expert Opin Investig Drugs, 2003, 12 (4):655.
  • 6Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety [J]. Expert Opin Pharmacother, 2002, 3(12): 1773.
  • 7Marcus R, Gharbia NA, Kujawa MJ, et al. Aripiprazole for longterm maintenance treatment of schizophrenia [A]. The 2002 annual meeting of the American College of Clinical Pharmacy [C], Albuquerque, New Mexico, Sage Science press, October 20～ 23, 2002.
  • 8Carson W, Pigott T, Saha A, et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia [A] . The 42nd annual meeting of the New Clinical Drug Evaluation Unit[C], Boca Raton,Florida, The National Institute of Mental Health,June 10 ～ 13, 2002.
  • 9Petrias JM, McQuade RD, Cassey DE, et al. Switch to aripiprazole monotherapy[A]. The 2002 annual meeting of the American College of Clinical Pharmacy[C], Albuquerque, New Mexico, Sage Science Press, October 20～23, 2002.
  • 10Kern RS, Cornblatt B, Carson WH, et al. An open-label comparison of the neurocognitive effects of aripiprazole vs. olanzapine in patients with stable psychosis [J]. Schizophr Res, 2001, 49 (Suppl 1～2):S234.

共引文献79

同被引文献30

  • 1解恒革,王鲁宁,于欣,王炜,杨丽娟,马腾霄,张晓红,杨丽君,许贤豪,彭丹涛,张振馨,魏镜,王荫华,贾建平,管小亭,冯峰.北京部分城乡社区老年人和痴呆患者神经精神症状的调查[J].中华流行病学杂志,2004,25(10):829-832. 被引量：48
  • 2安翠霞,于欣.痴呆患者经济负担及相关因素研究[J].中国心理卫生杂志,2005,19(9):592-594. 被引量：38
  • 3JORDAN S , KOPRIVICA V, CHEN R, et al . The antipsychotic aripiprazole is a potent , partial agonist at the human 5-HT 1A receptor [ J ]. Eur J Phamacol , 2002,441 (3) :137 - 140.
  • 4WILLNER P. The mesolimbic dopamine system as a target for rapid antidepressant action [ J ]. Int Clin Psychophamiacol, 1997,12( Suppl3 ) : 7 - 14.
  • 5THASE M E, CORYA S A, OSUNTOKUN O,et al. A randomized , double-blind comparison of olanzapine /fluoxetine combination , olanzapine , and fiuoxetine in treatment resistant major depressive disorder [ J ]. J Clin Psychiatry, 2007,68 ( 2 ) :224 - 236.
  • 6RAPAPORT M H ,GHARABAWI G M , CANUSO C M ,et al. Effects of risperidone augmentation in patients with treatment resistant depression, results of open-label treatment followed by double blind continuation [ J ]. Neuropsychopharmacology ,2006,31 ( 11 ) :2505 - 2513.
  • 7陈彦方.CCMD-3相关精神障碍的治疗与护理[M].济南:山东科学技术出版社,2008:198-201.
  • 8BANERJEE S, SMITH S C, LAMPING D C, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia [ J ]. J Neurosurg Psychiatry, 2006,77 ( 2 ) : 146-148.
  • 9CUMMINGS . Drug therapy: Alzheimer' s disease [ J ]. N Engl J Med,2004,351 ( 1 ) :56-67.
  • 10蔡经宇.瑞波西汀联合阿立哌唑治疗伴有精神病性症状的抑郁症对照研究[J].中国全科医学,2007,10(18):1522-1524. 被引量：9

引证文献5

二级引证文献15

医药导报
2009年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部